// App-Quantinova.ai

P5.362 : Evaluation of neurological improvements in secondary progressive multiple sclerosis patients treated with myeloid targeted immune modulator MIS416 (P5.362)

Researchers

Presenter

  • Gill Webster

Principal Investigators

  • Nancy Mayo

Medical Centers

  • Montreal University, Montreal, QC, Canada

  • Innate Immunotherapeutics Ltd., Auckland, New Zealand

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • MIS 416

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01191996

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved